Abstracts tagged "kinase and osteoclasts"

Abstract Number: 41 • 2018 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Improves Bone Strength in Mouse Model for Rheumatoid Arthritis
Ryuusuke Kaneko, Fumihito Hosoi, Satoru Iguchi, Hiroaki Hayashi, Yohei Yoshiga, Yoshinori Nakachi, Daichi Akasaka, Kenji Tanaka, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome. Although…
Abstract Number: 1824 • 2013 ACR/ARHP Annual Meeting
ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation
Yuko Ariza¹, Toshio Yoshizawa¹, Yoshiko Ueda¹, Shingo Hotta¹, Tomoko Yasuhiro¹, Masami Narita¹, Yutaka Shichino² and Kazuhito Kawabata¹, ¹Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ²Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by leukocyte infiltration, synoviocyte hyperplasia and osteoclastogenesis, leading to erosion of the joints and cartilage,…
Abstract Number: 2086 • 2012 ACR/ARHP Annual Meeting
PI3-Kinase Controls Inflammatory Bone Destruction by Regulating the Osteoclastogenic Potential of Myeloid Cells
Stephan Blueml¹, Gernot Schabbauer², Antonia Puchner³, Emine Sahin², Victoria Saferding⁴, Birgit Niederreiter⁵, Josef S. Smolen⁶ and Kurt Redlich⁵, ¹Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Vascular Biology and Thrombosis research, Medical University Vienna, Vienna, Austria, ³Dpt of Rheumatology, Medical University Vienna, Vienna, Austria, ⁴Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Local bone destruction in rheumatoid arthritis, psoriasisarthritis or ankylosing spondylitis is a serious health burden and the major cause of disability and severely reduced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].